A Phase 1 Multiple Ascending Oral Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2017
At a glance
- Drugs ASP 4345 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Astellas Pharma
- 12 Sep 2017 Status changed from recruiting to completed.
- 20 Jun 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.
- 20 Jun 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2017.